November, 2022

article thumbnail

AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments

Fierce Pharma

AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments. aliu. Thu, 11/10/2022 - 09:02.

364
364
article thumbnail

AI will continue to attract investment in near future in the healthcare industry

Pharmaceutical Technology

Artificial intelligence (AI) was seen as one of the top current investment priorities and was thought to continue to attract investment in the healthcare sector in the upcoming two years, according to GlobalData's latest report ‘Digital Transformation and Emerging Technology in the Healthcare Industry - 2022 Edition’. In this survey-based report tracker, digital media was prioritised as a top current investment target, with 53% of surveyed respondents confirming that their companies are currentl

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why are Healthcare Costs So High? Blame the Middlemen

MedCity News

Large employers, particularly self-insured companies, can demand a better and fairer system. They can use their contracting power to insist that their plans cover all FDA approved drugs.

FDA 143
article thumbnail

Could digital therapeutics provide a solution against opioid abuse?

pharmaphorum

Digital therapeutics are rapidly coming into the foreground to treat a variety of conditions. Ben Hargreaves discovers how chronic pain could be a key area for digital therapeutics, as they offer non-addictive and effective relief from the condition. The struggle to manage pain for individuals has been one that goes back a long way in history, with one of the earliest recorded medical prescriptions being for opium.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Device Measures Hemoglobin More Accurately in Dark Skin

Medgadget

Researchers at the University of Texas at Arlington, in collaboration with Shani Biotechnologies, a local firm, have created a point-of-care device that can accurately measure hemoglobin levels and perform pulse oximetry in individuals with dark skin. At present, methods to determine hemoglobin levels at the point of care, such as pulse oximetry, are inaccurate in individuals with higher levels of melanin in their skin, and there is a clear need to develop alternatives that work for everyone.

Patients 133

More Trending

article thumbnail

Moderna can't hide behind the government in patent infringement suit, judge rules

Fierce Pharma

Moderna can't hide behind the government in patent infringement suit, judge rules. zbecker. Thu, 11/03/2022 - 15:47.

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

In a field dominated by antibodies and small molecules, two cell-therapy based approaches have come under the spotlight for showing early signs of efficacy in treating lupus. In September, a group from Friedrich Alexander University Erlangen-Nuremberg reported that five patients with lupus achieved remission after an infusion of autologous chimeric antigen receptor (CAR)-T cells led to a deep depletion of B cells.

Patients 144
article thumbnail

Two Pharmacy Owners Plead Guilty in $18M Foreign Medicare Fraud Scheme

MedCity News

The scheme started in New York but became a complex international endeavor as the two men attempted to launder money received from fraudulent Medicare claims for cancer drugs during the pandemic.

article thumbnail

Advanced therapies and the high-profile pricing dilemma

pharmaphorum

The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in smaller patient populations. However, alongside this progress, Ben Hargreaves finds that there is also a conundrum over how to price these therapies. It is no secret that the drug development process for the pharmaceutical industry has undergone a major transition in the last few decades.

Medicine 131
article thumbnail

MHRA approves first gene therapy for infusion into the brain

European Pharmaceutical Review

Upstaza (eladocagene exuparvovec) is the first and only approved treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and is the first marketed gene therapy for direct infusion into the brain. The product, produced by biopharma company PTC Therapeutics, is approved for patients 18 months and over. It has been granted marketing authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain.

Biopharma 125
article thumbnail

A Culture of Quality: The Catalyst to Accelerate Innovation

PharmExec

Why enabling a shared culture of quality across an organization is key to maintaining pharma’s recent pace of innovation wins—while inspiring new levels of confidence.

128
128
article thumbnail

Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says

Fierce Pharma

Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says. zbecker. Tue, 11/08/2022 - 11:03.

315
315
article thumbnail

Cyagen and Neurophth partner to develop gene therapy vectors

Pharmaceutical Technology

Cyagen and Neurophth Therapeutics have entered a strategic partnership to jointly develop next-generation AAV gene therapy vectors for specific kinds of genetic ophthalmic ailments. According to the deal, Cyagen will leverage its artificial intelligence (AI)-driven high-throughput platform for discovering new AAV vectors with enhanced tissue targeting expertise, tissue specificity and productivity. .

article thumbnail

Beware of a False Sense of Cybersecurity

MedCity News

Based on some independent research that my company commissioned with more than 200 companies, we came to several conclusions that are highlighted in the article. Broadly, however, it signals the false sense of (cyber)security that many companies are currently harboring.

Patients 137
article thumbnail

Data privacy concerns don’t hinder digital health app usage

pharmaphorum

A new survey conducted by juli, an AI-powered chronic condition platform, has revealed that the value placed on digital privacy differs widely among US users. With the HLTH 2022 event now well underway, digital health industry leaders all gathered together to attend in Las Vegas this week, the juli survey results reveal consumer responses to be more varied than one would have expected when it comes to data privacy.

Patients 130
article thumbnail

FDA approves first gene therapy for Haemophilia B

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Hemgenix (etranacogene dezaparvovec), the first gene therapy for adults with Haemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening haemorrhage, or have repeated, serious spontaneous bleeding episodes. Standard treatment for the condition involves replacing the missing or deficient clotting factor to improve the body’s ability to stop bleeding and promot

FDA 124
article thumbnail

The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

PharmaVoice

Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

article thumbnail

Nothing to sneeze at: AstraZeneca donates thousands of nasal spray flu vaccines after Swiss pricing row

Fierce Pharma

Nothing to sneeze at: AstraZeneca donates thousands of nasal spray flu vaccines after Swiss pricing row. fkansteiner. Thu, 11/17/2022 - 13:27.

302
302
article thumbnail

NHS expedites rollout of Bayer’s darolutamide for prostate cancer

Pharmaceutical Technology

The National Health Service (NHS) in England, UK, has expedited the rollout of Bayer ’s new life-extending drug, darolutamide, to treat the most advanced kinds of prostate cancer that have spread to other body parts. With the latest development, NHS will become the first healthcare system in Europe to offer this drug to prostate cancer patients. Nearly 9,000 men with prostate cancer will be eligible to receive this treatment.

Patients 118
article thumbnail

Firefly, Sprinter Team Up to Close the Loop on Virtual Primary Care

MedCity News

Sprinter Health is integrating its at-home clinical and diagnostic services into Firefly Health’s virtual primary care model. Firefly’s members will be able to receive common medical services from Sprinter clinicians in their homes — such as vital checks, blood draws, electrocardiograms, diabetic eye exams and diabetic foot screenings.

Medical 138
article thumbnail

First human trials of lab-grown red blood cells start in UK

pharmaphorum

Blood cells grown in a laboratory have been given to people for the first time in a clinical trial being carried out by researchers in the UK, in the hope that plentiful supplies of rare blood groups can be manufactured to order. A team from the universities of Bristol and Cambridge, NHS trusts and NHS Blood and Transplant (NHSBT) have started giving small quantities of the lab-grown red blood cells – a couple of teaspoons full – to two healthy volunteers to see if they are safe.

Patients 126
article thumbnail

“Universal” CRISPR-edited T cells improve resistant leukaemia

European Pharmaceutical Review

Researchers at Great Ormond Street Hospital for Children (GOSH) and University College London (UCL) Great Ormond Street Institute of Child Health (UCL GOS ICH) have used “universal” CRISPR-edited cells in humans for the first time to treat B-cell acute lymphoblastic leukaemia (B-ALL) child patients with engineered donor T cells. The treatment did not require matching donor cells, a major step in developing gene-edited cells for cancer treatment.

Patients 125
article thumbnail

Implantable Device Adheres to Muscle, Treats Atrophy

Medgadget

Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard have developed a mechanically active gel-elastomer-nitinol tissue adhesive, otherwise known as MAGENTA. The implantable device functions as a soft robot, and it can be adhered to the outside of a muscle. When an electrical charge is applied to the device, a spring inside made from nitinol (a shape memory alloy) heats up and begins to actuate, creating a contraction and stretching effect on the attached muscle.

Medicine 116
article thumbnail

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line

Fierce Pharma

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line. zbecker. Wed, 11/23/2022 - 10:10.

FDA 304
article thumbnail

Pfizer records 6% decline in revenue in Q3 2022

Pharmaceutical Technology

Pfizer has reported a 6% decline in revenue to $22.6bn in the third quarter (Q3) of 2022 as against $24bn in the same quarter last year. In the quarter, revenues rose 2% operationally on omitting contributions from Covid-19 therapies, Paxlovid and Comirnaty. Reduction in revenues from Comirnaty outside the US and reduced revenues for some Comirnaty-linked manufacturing works carried out on behalf of BioNTech, Xeljanz and Sutent worldwide were the key drivers that contributed to the revenue dec

article thumbnail

Report: Health Insurance Is Influencing Americans’ Job Choices

MedCity News

More than 31% of people with employer-sponsored insurance stuck with a job they disliked for the company’s health insurance, a Forbes Advisor survey found. Another 8% of respondents left a job they liked to seek better coverage.

Insurance 137
article thumbnail

Novartis said to be eyeing sale of ophthalmology, respiratory units

pharmaphorum

Novartis has already spun out its eyecare business Alcon, and is now considering the sale of its ophthalmology and respiratory medicines businesses as it continues a narrowing of its focus, according to media reports. A Bloomberg article citing people close to the matter claims that Novartis is engaged in early discussions about the sale of the two units, which could raise billions of dollars in capital that could be reinvested into the pharma group’s pipeline.

Sales 124
article thumbnail

First-in-human gene therapy trial for major cardiac syndrome

European Pharmaceutical Review

The first-in-human gene therapy trial for heart failure patients with preserved ejection fraction (HFpEF) has been approved by the US Food & Drug Administration (FDA). SRD-001, the adenovirus associated virus (AAV)-based gene therapy is delivered to cardiac ventricular muscle cells via an intracoronary infusion system (produced by Sardocor, a clinical-stage gene therapy subsidiary of Medera), to increase the protein expression and functional activity of sarcoplasmic reticulum calcium ATPase

article thumbnail

Extra Hot Nanoparticles for Cancer Therapy

Medgadget

Researchers at Oregon State University created a new type of hyperthermic magnetic nanoparticle that is intended to assist in destroying tumors through localized heating under an alternating magnetic field. Previous iterations of such technologies could heat up to about 44 degrees Celsius (111 F), which was only effective in easy-to-access tumors that can be reached with a hypodermic needle, allowing a clinician to inject a large number of the nanoparticles directly into the tumor.

article thumbnail

Pfizer boosts COVID vaccine projection to $34B on the back of strong Comirnaty haul

Fierce Pharma

Pfizer boosts COVID vaccine projection to $34B on the back of strong Comirnaty haul. kdunleavy. Tue, 11/01/2022 - 11:29.

310
310
article thumbnail

5 enduring mysteries of the Barry and Honey Sherman murders

PharmaVoice

After nearly five years, the homicide case involving pharma billionaires continues to perplex investigators.

Pharma 144
article thumbnail

How Behavioral Healthcare Practices Can Reduce No-show Appointments

MedCity News

By taking a few simple steps, practices can help ensure that their patients get the care they need while reducing unnecessary losses of revenue and time within the business model.

article thumbnail

Artificial Intelligence for better antibody drugs: ready for prime time?

pharmaphorum

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were mAbs and this trend is forecasted to remain the same over the next five years. Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline.

Biopharma 123